Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors
This was the stock's third consecutive day of losses.
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation [...]
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the ...
Corbus announces first patient dosed in Phase 1 CRB-913 study
Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 2.35% to $6.10 Tuesday, on what proved to be an all-around positive ...